Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteAG-120 (racemic), the racemic mixture of AG-120, is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1) with potential antineoplastic activity.
More Information Supplier PageAG-120 (racemic), the racemic mixture of AG-120, is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1) with potential antineoplastic activity.
More Information Supplier PageAG126 is a tyrosine kinase inhibitor which selectively inhibits the phosphorylation of ERK1 (p44) and ERK2 (p42) at 25-50 μM.
More Information Supplier PageAG-13958 (AG-013958), a VEGFR tyrosine kinase inhibitor, is in clinical development with ST administration for treatment of choroidal neovascularization associated with age–related macular degeneration (AMD).
More Information Supplier PageAG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
More Information Supplier PageAG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
More Information Supplier PageAG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
More Information Supplier PageAG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
More Information Supplier PageAG-1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.
More Information Supplier PageAG-18 (RG-50810, Tyrphostin A23, TX 825) inhibits EGFR with IC50 of 35 μM.
More Information Supplier PageAG-270 is a potent and non-competitive methionine adenosyltransferase 2A (MAT2A) inhibitor which lessens the intracellular SAM levels and MTAP-null–selective antiproliferative activity.
More Information Supplier PageAG-270 is a potent and non-competitive methionine adenosyltransferase 2A (MAT2A) inhibitor which lessens the intracellular SAM levels and MTAP-null–selective antiproliferative activity.
More Information Supplier PageAG-270 is a potent and non-competitive methionine adenosyltransferase 2A (MAT2A) inhibitor which lessens the intracellular SAM levels and MTAP-null–selective antiproliferative activity.
More Information Supplier PageAG-270 is a potent and non-competitive methionine adenosyltransferase 2A (MAT2A) inhibitor which lessens the intracellular SAM levels and MTAP-null–selective antiproliferative activity.
More Information Supplier PageAG-490 is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
More Information Supplier PageAG-490 is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
More Information Supplier PageAG-636 is an orally available inhibitor of dihydroorotate dehydrogenase (DHODH) with potential antineoplastic activity.
More Information Supplier PageAG-636 is an orally available inhibitor of dihydroorotate dehydrogenase (DHODH) with potential antineoplastic activity.
More Information Supplier PageAG99 (Tyrphostin 46,Tyrphostin A46,Tyrphostin B40) is a potent and selective inhibitor of EGFR.
More Information Supplier PageAgar is a jelly like substance that contains agarose and agar gel isolated from the cell walls of red algae species such as Gelidium and Gracilaria (Ogonori). It is widely used in food additives, plant tissue culture, microorganisms culture media, fingerprint recognition, and medical fields.
More Information Supplier PageAgar is a jelly like substance that contains agarose and agar gel isolated from the cell walls of red algae species such as Gelidium and Gracilaria (Ogonori). It is widely used in food additives, plant tissue culture, microorganisms culture media, fingerprint recognition, and medical fields.
More Information Supplier PageAgaric Extract is extracted from agaricales, which has anti-inflammatory and related pharmacological activities.
More Information Supplier PageAgaricus blazei Extract is extracted from Agaricus blazei Murill, which is believed to have anti-tumor and antioxidative activities.
More Information Supplier PageAgarotetrol is a chromone derivative found in high concentrations in the water-extract fraction of agarwood. Agarotetrol contributes to the fragrance of agarwood through the generation of LACs upon heating.
More Information Supplier PageAgerafenib (CEP-32496) is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret (c-Ret), PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. Phase 1/2.
More Information Supplier PageAGI-1067 is a novel, phenolic, intra- and extracellular antioxidant that inhibits the expression of a number of proinflammatory genes involved in atherosclerosis.
More Information Supplier PageAGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
More Information Supplier PageAGI-5198 (IDH-C35) is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
More Information Supplier PageAGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.
More Information Supplier PageAGI-6780 is a potent and selective inhibitor of IDH2 R140Q mutant with IC50 of 23 nM.
More Information Supplier PageAGK2 is a potent, and selective SIRT2 inhibitor with IC50 of 3.5 μM that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.
More Information Supplier PageAGK2 is a potent, and selective SIRT2 inhibitor with IC50 of 3.5 μM that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.
More Information Supplier PageAGK2 is a potent, and selective SIRT2 inhibitor with IC50 of 3.5 μM that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.
More Information Supplier PageAgomelatine (Valdoxan, Melitor, Thymanax,S20098) is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor.
More Information Supplier PageAgrimonia pilosa Extract is obtained from Agrimonia pilosa Ledeb., which has shown remarkable effectiveness in the treatment of various diseases, especially enteritis, gastric ulcers, and gastrointestinal bleeding.
More Information Supplier PageAGX51, a first-in-class pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist and degrader, inhibits the Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and reduces viability, also inhibits pathologic ocular neovascularization.
More Information Supplier PageAGX51, a first-in-class pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist and degrader, inhibits the Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and reduces viability, also inhibits pathologic ocular neovascularization.
More Information Supplier PageAGX51, a first-in-class pan-Id (inhibitors of DNA-binding/differentiation proteins) antagonist and degrader, inhibits the Id1-E47 interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and reduces viability, also inhibits pathologic ocular neovascularization.
More Information Supplier PageAH7614 (compound 39) is a selective FFA4 (GPR120) antagonist with pIC50s of 7.1 for human FFA4 and 8.1 for mouse FFA4.
More Information Supplier PageAH7614 (compound 39) is a selective FFA4 (GPR120) antagonist with pIC50s of 7.1 for human FFA4 and 8.1 for mouse FFA4.
More Information Supplier PageAI-10-49 is a selective inhibitor of the binding of CBFβ-SMMHC to RUNX1 with IC50 of 260 nM.
More Information Supplier PageAI-10-49 is a selective inhibitor of the binding of CBFβ-SMMHC to RUNX1 with IC50 of 260 nM.
More Information Supplier PageAICAR (Acadesine, NSC105823, AICA Riboside), an AMPK activator, results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. AICAR (Acadesine) induces mitophagy. Phase 3.
More Information Supplier PageAICAR (Acadesine, NSC105823, AICA Riboside), an AMPK activator, results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. AICAR (Acadesine) induces mitophagy. Phase 3.
More Information Supplier PageAICAR (Acadesine, NSC105823, AICA Riboside), an AMPK activator, results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. AICAR (Acadesine) induces mitophagy. Phase 3.
More Information Supplier PageAICAR (Acadesine, NSC105823, AICA Riboside), an AMPK activator, results in accumulation of ZMP, which mimics the stimulating effect of AMP on AMPK and AMPK kinase. AICAR (Acadesine) induces mitophagy. Phase 3.
More Information Supplier Page
